At present, a number of new biological drugs have been created for major diseases such as autoimmunity, tumors, and ophthalmology.
It is learned that Rongchang Biopharmaceutical (Yantai) Co., Ltd. (hereinafter referred to as “Rongchang Bio”) has Completed more than 100 million US dollars financing, led by Eli Lilly Asia Fund and Qingchi Capital, investment institutions such as Weiwu Capital, Jianye Industrial Investment, Aobo Capital, Hudson Bay Capital and the company’s original investors jointly participated in the investment. In addition, Zhengxingu and Guoxin Overseas also subscribed for some equity through equity transfer.
It is reported that the financing obtained by Rongchang Biological will be used to accelerate the development of new drugs for the company’s R & D pipeline, especially clinical trials, and the construction and production of commercial production bases, including systemic lupus erythematosus (SLE) new drug Tatarxi Preparations for the commercial production of Raptor (RC18) and antibody-drug conjugate (ADC) drug Idisch (RC48).
Rongchang Bio was co-sponsored by Rongchang Pharmaceutical and Professor Fang Jianmin, a scientist from the United States, in 2008. It focuses on the research and development of innovative genetically engineered drugs with independent intellectual property rights. It has been created for autoimmune, tumor, ophthalmology and other major diseases A batch of new biological drugs has been produced, of which 5 drug molecules have entered the clinical trial stage.
Among them, Tatarcept (RC18) is a dual-targeted biological drug for the treatment of autoimmune diseases, and has applied to the State Food and Drug Administration for the listing of new drugs; Aidexi (RC48) is the first ADC drug to enter human clinical trials in China. Key clinical trials for tumors such as gastric cancer and urothelial cancer are currently underway.
target=”_blank”> study that the effective rate of the RC18 high-dose group is as high as 79.2%, and it has the characteristics of a new structure, a new mechanism, and a new target. “First-in-class” of bio-innovative drugs.
At present, new drugs for treating SLE on the market are very rare. The development of new drugs is extremely difficult. In recent years, many international projects have ended in failure. Since hydroxychloroquine in 1955, the US FDA has approved only one new drug for the treatment of SLE in the past 60 years. It is understood that RC18 is a new biological drug for autoimmune diseases related to B lymphocytes. In addition to conquering SLE, clinical trials for multiple indications are ongoing. the study.
RC48 has entered human clinical trials, which also marks a breakthrough in ADC drug technology in China. ADC drugs are conjugated with monoclonal antibodies, linkers and toxins. They can precisely attack cancer cells like precision guided missiles, which is an important frontier for the development of anticancer drugs in the world. RC48 uses the HER2 protein on the surface of tumor cells as a target, and has shown great potential in clinical research on breast cancer, gastric cancer, urothelial cancer and other malignant tumors.
In terms of team, Rongchang Biotechnology has gathered a team with rich experience in new molecular discovery, process development, GMP production, clinical research, marketing and other aspects of biomedicine. Its founder and CEO, Fang Jianmin The professor is a well-known scientist in the United States. He has invented many innovative drug molecules and achieved many breakthrough results.